HeartSciences Inc.
HeartSciences Inc.
Your view on HSCSW
Overview
What the company does, where it operates, and who runs it.
About HeartSciences Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Andrew Simpson
- Headquarters
- 550 Reserve Street, Southlake, TX, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Andrew Simpson
- Headquarters
- 550 Reserve Street, Southlake, TX, US
Heart Test Laboratories, Inc. is a medical technology enterprise dedicated to the creation of diagnostic instruments for cardiovascular health. The company's primary offering is the MyoVista wavECG, a sophisticated 12-lead resting electrocardiograph.
This device provides essential diagnostic insights into cardiac dysfunction, in addition to supplying standard 12-lead resting ECG information. Serving a diverse range of medical environments, its products are adopted by clinics, physicians' offices, urgent care centers, and hospitals.
Founded in 2007, the firm's operations are headquartered in Southlake, Texas.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for HeartSciences Inc., and the rating behind it. HSCSW last traded at $0.08; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for HeartSciences Inc.. Starting points for HeartSciences Inc.: EPS -$2.80, beta 1.86 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for HeartSciences Inc.. HeartSciences Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for HeartSciences Inc.. Trailing twelve-month EPS for HeartSciences Inc. stands at -$2.80. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for HeartSciences Inc.. HeartSciences Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
HeartSciences Inc. valued side by side against its closest peers. HeartSciences Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold HeartSciences Inc., and how their positions are changing. At a $218,171 market value, institutional positions materially move HeartSciences Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by HeartSciences Inc. executives and directors. Shares of HeartSciences Inc. have traded between $0.04 and $0.07 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming HeartSciences Inc.. HeartSciences Inc. is a $218,171 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming HeartSciences Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for HeartSciences Inc.. Coverage tracks HeartSciences Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.